Amylyx Pharmaceuticals Etf Performance
| AMLX Etf | USD 3.78 0.13 3.56% |
The etf shows a Beta (market volatility) of 1.42, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Amylyx Pharmaceuticals will likely underperform.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Amylyx Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong essential indicators, Amylyx Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Disposition of 27910 shares by Milne George M Jr of Amylyx Pharmaceuticals subject to Rule 16b-3 | 01/24/2025 |
2 | Disposition of 32000 shares by Frates James M of Amylyx Pharmaceuticals at 26.9266 subject to Rule 16b-3 | 01/29/2025 |
3 | Disposition of 11855 shares by Justin Klee of Amylyx Pharmaceuticals at 3.4672 subject to Rule 16b-3 | 02/03/2025 |
4 | Disposition of 36310 shares by Justin Klee of Amylyx Pharmaceuticals at 1.57 subject to Rule 16b-3 | 02/05/2025 |
5 | SG Americas Securities LLC Reduces Holdings in Amylyx Pharmaceuticals, Inc. - Defense World | 02/14/2025 |
6 | Insider Trading | 02/19/2025 |
7 | Disposition of 4169 shares by Gina Mazzariello of Amylyx Pharmaceuticals at 3.153 subject to Rule 16b-3 | 02/24/2025 |
8 | Acquisition by Frates James M of 40000 shares of Amylyx Pharmaceuticals at 2.5342 subject to Rule 16b-3 | 02/26/2025 |
9 | Amylyx Pharmaceuticals, Inc. Insider Gina Mazzariello Sells 4,169 Shares | 02/27/2025 |
10 | Amylyx Pharmaceuticals Inc Q4 2024 Everything You Need To Know Ahead Of Earnings | 03/03/2025 |
11 | Q4 2024 Amylyx Pharmaceuticals Inc Earnings Call Transcript | 03/05/2025 |
12 | Acquisition by Frates James M of 102630 shares of Amylyx Pharmaceuticals at 3.61 subject to Rule 16b-3 | 03/06/2025 |
13 | Acquisition by Zeiher Bernhardt G of 10000 shares of Amylyx Pharmaceuticals at 3.7005 subject to Rule 16b-3 | 03/20/2025 |
| Begin Period Cash Flow | 170.9 M | |
| Free Cash Flow | -167.8 M |
Amylyx |
Amylyx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 400.00 in Amylyx Pharmaceuticals on December 24, 2024 and sell it today you would lose (22.00) from holding Amylyx Pharmaceuticals or give up 5.5% of portfolio value over 90 days. Amylyx Pharmaceuticals is currently generating 0.0176% in daily expected returns and assumes 4.7147% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of etfs are less volatile than Amylyx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amylyx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amylyx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as Amylyx Pharmaceuticals, and traders can use it to determine the average amount a Amylyx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0037
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AMLX |
Estimated Market Risk
| 4.71 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amylyx Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amylyx Pharmaceuticals by adding Amylyx Pharmaceuticals to a well-diversified portfolio.
Amylyx Pharmaceuticals Fundamentals Growth
Amylyx Etf prices reflect investors' perceptions of the future prospects and financial health of Amylyx Pharmaceuticals, and Amylyx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amylyx Etf performance.
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | 61.13 % | ||||
| Current Valuation | 148.88 M | ||||
| Shares Outstanding | 88.6 M | ||||
| Price To Book | 1.96 X | ||||
| Price To Sales | 3.70 X | ||||
| Revenue | 87.37 M | ||||
| EBITDA | (290.98 M) | ||||
| Cash And Equivalents | 206.68 M | ||||
| Cash Per Share | 3.53 X | ||||
| Total Debt | 1.98 M | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 2.40 X | ||||
| Cash Flow From Operations | (167.65 M) | ||||
| Earnings Per Share | (4.43) X | ||||
| Total Asset | 193.63 M | ||||
| Retained Earnings | (606.69 M) | ||||
About Amylyx Pharmaceuticals Performance
Evaluating Amylyx Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Amylyx Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amylyx Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.| Amylyx Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 87.37 M. Net Loss for the year was (301.74 M) with loss before overhead, payroll, taxes, and interest of (141.35 M). | |
| Amylyx Pharmaceuticals currently holds about 206.68 M in cash with (167.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.53. | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Zeiher Bernhardt G of 10000 shares of Amylyx Pharmaceuticals at 3.7005 subject to Rule 16b-3 |
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.